5 active not recruiting, 2 completed, 1 recruiting. 8 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Active not recruiting 5, Completed 2, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow encorafenib: new trials by email Literature Review of encorafenib trials Research Report on encorafenib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer Encorafenib, Cetuximab, Biospecimen Collection - Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma | Phase 2 / Phase 3 | Active not recruiting | Alliance for Clinical Trials in Oncology | 1 | 2023-08-16 | 2026-07-02 |
| Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. Encorafenib and Binimetinib, Placebo to match Encorafenib ; Placebo to match Binimetinib - Melanoma | Phase 3 | Active not recruiting | Pierre Fabre Medicament | 815 | 2022-05-02 | 2023-11-22 |
| A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma Encorafenib, Binimetinib, Pembrolizumab - Melanoma | Phase 3 | Active not recruiting | Pfizer | 257 | 2021-01-15 | 2026-09-03 |
| A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer Encorafenib, Cetuximab, Oxaliplatin - Neoplasms | Phase 3 | Active not recruiting | Pfizer | 841 | 2020-12-21 | 2026-06-11 |
| Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer FOLFIRI Protocol, ACTIVE SURVEILLANCE, Nivolumab Protocol - Metastatic Colon Cancer, Stage III Colon Cancer | Phase 3 | Active not recruiting | Massachusetts General Hospital | 400 | 2020-04-16 | 2026-09-09 |
| Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Encorafenib, Binimetinib, Cetuximab - BRAF V600E-mutant Metastatic Colorectal Cancer | Phase 3 | Completed | Pfizer | 702 | 2016-10-13 | 2023-12-21 |
| Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma LGX818, MEK162, vemurafenib - Melanoma | Phase 3 | Completed | Pfizer | 921 | 2013-09-12 | 2026-02-27 |
Colonic Neoplasms (3) · Melanoma (3) · Colorectal Neoplasms (2) · Neoplasms (2) · Skin Neoplasms (2) · Biliary Tract Neoplasms (1) · Colonic Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Intestinal Diseases (1) · Intestinal Neoplasms (1) · Neoplasm Metastasis (1) · Rectal Diseases (1)
Pfizer (4) · Alliance for Clinical Trials in Oncology (1) · Massachusetts General Hospital (1) · Pierre Fabre Medicament (1) · UNICANCER (1)
United Kingdom (6) · United States (6) · Argentina (5) · Belgium (5) · Brazil (5) · Canada (5) · Czechia (5) · France (5) · Germany (5) · Italy (5) · Norway (5) · Poland (5) · Spain (5) · Australia (4) · Hungary (4)
Aparna Parikh, MD (1) · Ivan Borbath, MD (1) · John Bridgewater, MD (1) · Juan W Valle (1) · Julien Edeline, MD (1) · Malka David, MD (1)
PMID 29573941, PMID 30219628, PMID 30892987, PMID 31437754, PMID 31566309, PMID 33503393, PMID 34091420, PMID 34655839, PMID 35272485, PMID 35653981, PMID 35654691, PMID 35862871, PMID 36653241, PMID 36653848, PMID 36763936, PMID 37309702, PMID 37506329, PMID 37534686, PMID 37665297, PMID 39313594, PMID 39863775, PMID 40444708, PMID 41230651
2015 (1), 2023 (1)